Elicio Therapeutics, Inc.

ELTX

US28657F1030

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 03:30:00 05/07/2024 am IST			5-day change	1st Jan Change
3.67 ^USD	-0.27%		-10.71%	-56.00%

01/07	Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell Microcap Growth Index	CI
01/07	Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Index	CI

Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Growth Index

July 01, 2024

Latest news about Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell Microcap Growth Index	01/07	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Index	01/07	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell Microcap Index	01/07	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Growth Index	01/07	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell Microcap Value Index	01/07	CI
Elicio Therapeutics, Inc.(NasdaqGM:ELTX) added to Russell 3000E Value Index	01/07	CI
Elicio Therapeutics Stock Falls After $11.5 Million Underwritten Public Offering Priced	28/06	MT
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	28/06	MT
Sector Update: Health Care Stocks Higher Pre-Bell Friday	28/06	MT
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell	28/06	MT
Top Premarket Decliners	28/06	MT
Elicio Therapeutics Launches Public Offering; Shares Tumble After-Hours	28/06	MT
Elicio Therapeutics, Inc. Announces Preliminary Disease-Free Survival Analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P	28/06	CI
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting	24/05	CI
Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting	06/04	CI
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC	19/03	CI
Elicio Therapeutics, Inc. announced that it expects to receive $5.999999 million in funding from Gkcc, LLC	18/03	CI
Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	25/01	CI
Elicio Therapeutics Reports First Patient Dosed in Mid-Stage Pancreatic Cancer Trial	12/01	MT
Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study	11/01	CI
Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	09/01	CI
Elicio Therapeutics, Inc. announced that it has received $7.04753 million in funding	22/12	CI
Elicio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI

Chart Elicio Therapeutics, Inc.

Duration

Period

More charts

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.67 USD

Average target price

10 USD

Spread / Average Target

+172.48%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ELICIO THERAPEUTICS, INC.	-56.00%	39.47M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research